Donor and transplant characteristics
| Characteristics . | Data (N = 129) . |
|---|---|
| Donor matching | |
| HLA-matched sibling | 22 (17) |
| HLA-mismatched related* | 2 (2) |
| HLA-matched unrelated (10 of 10) | 41 (32) |
| HLA-mismatched unrelated (≤ 9 of 10) | 21 (16) |
| Unrelated CB | 39 (30) |
| 6 of 6 | 13 (10) |
| 5 of 6 | 20 (15) |
| 4 of 6 | 6 (5) |
| Unrelated donor, match unknown | 4 (3) |
| Hematopoietic stem cell source | |
| Bone marrow† | 80 (62) |
| PBSC | 10 (8) |
| CB | 39 (30) |
| Conditioning regimen‡ | |
| Myeloablative | 88 (68) |
| Busulfan/cyclophosphamide | 80 (62) |
| Busulfan/fludarabine | 3 (2) |
| Busulfan/melphalan | 1 (1) |
| MAC (other) | 4 (3) |
| Reduced intensity | 39 (30) |
| Busulfan/cyclophosphamide | 8 (6) |
| Busulfan/fludarabine | 17 (13) |
| RIC (other) | 14 (11) |
| Fludarabine/melphalan ± thiotepa | 12 (9) |
| Other | 2 (2) |
| Unknown intensity | 2 (2) |
| Busulfan/fludarabine | 2 (2) |
| Serotherapy | |
| Yes | 123 (95) |
| Rabbit or horse ATG | 99 (76) |
| Alemtuzumab | 24 (19) |
| No | 6 (5) |
| GVHD prophylaxis | |
| CNI alone | 2 (2) |
| CNI+MTX | 41 (32) |
| CNI+MMF | 21 (16) |
| CNI+steroids | 49 (38) |
| CNI+steroids+MTX | 11 (8) |
| CNI+steroids+MMF | 1 (1) |
| None | 4 (3)§ |
| T-cell depletion | |
| Yes | 5 (4) |
| No | 124 (96) |
| Characteristics . | Data (N = 129) . |
|---|---|
| Donor matching | |
| HLA-matched sibling | 22 (17) |
| HLA-mismatched related* | 2 (2) |
| HLA-matched unrelated (10 of 10) | 41 (32) |
| HLA-mismatched unrelated (≤ 9 of 10) | 21 (16) |
| Unrelated CB | 39 (30) |
| 6 of 6 | 13 (10) |
| 5 of 6 | 20 (15) |
| 4 of 6 | 6 (5) |
| Unrelated donor, match unknown | 4 (3) |
| Hematopoietic stem cell source | |
| Bone marrow† | 80 (62) |
| PBSC | 10 (8) |
| CB | 39 (30) |
| Conditioning regimen‡ | |
| Myeloablative | 88 (68) |
| Busulfan/cyclophosphamide | 80 (62) |
| Busulfan/fludarabine | 3 (2) |
| Busulfan/melphalan | 1 (1) |
| MAC (other) | 4 (3) |
| Reduced intensity | 39 (30) |
| Busulfan/cyclophosphamide | 8 (6) |
| Busulfan/fludarabine | 17 (13) |
| RIC (other) | 14 (11) |
| Fludarabine/melphalan ± thiotepa | 12 (9) |
| Other | 2 (2) |
| Unknown intensity | 2 (2) |
| Busulfan/fludarabine | 2 (2) |
| Serotherapy | |
| Yes | 123 (95) |
| Rabbit or horse ATG | 99 (76) |
| Alemtuzumab | 24 (19) |
| No | 6 (5) |
| GVHD prophylaxis | |
| CNI alone | 2 (2) |
| CNI+MTX | 41 (32) |
| CNI+MMF | 21 (16) |
| CNI+steroids | 49 (38) |
| CNI+steroids+MTX | 11 (8) |
| CNI+steroids+MMF | 1 (1) |
| None | 4 (3)§ |
| T-cell depletion | |
| Yes | 5 (4) |
| No | 124 (96) |
Data are number of recipients (percentage of total study group).
ATG, anti-thymocyte globulin.
Two patients received HLA-mismatched related grafts that included a 5- of 8-HLA–mismatched relative and a 9- of 10-HLA–matched sibling graft.
Two patients received bone marrow plus CB from their siblings.
Of the 108 patients who received busulfan/cyclophosphamide or busulfan/fludarabine, AUC data were available in 89 patients and were used for classification of MAC (n = 64) and RIC (n = 25). Two additional patients who received busulfan/fludarabine could not be classified because of lack of information and were excluded from analyses comparing MAC and RIC.
Four patients who received TCD grafts received no additional immune suppression for GVHD prophylaxis.